Introduction
Diabetic retinopathy is an important public health problem. It is the main cause of blindness in diabetics' and the most important cause of blindness during adult working life.2 At present we cannot prevent the inception of diabetic retinopathy. Early detection of this disorder by screening, however, followed by appropriate intervention may offer a practical means of preventing the resulting blindness.
There are several criteria which need to be satisfied if a screening programme is to prove worth while. 3 The disorder for which screening is to be conducted should be well defined, and estimates of its prevalence and rate of progression should be available; there should be an effective treatment; the screening test should be simple and safe and capable of discriminating adequately between affected and unaffected people; those with a positive test result should have a sufficiently high chance of being affected; the facilities for a screening programme should be available or easily installed; and the programme should be cost effective.
We review the evidence on screening for diabetic retinopathy in the light of these criteria and provide a quantitative assessment of the implications of mounting a screening programme for diabetic retinopathy in England and Wales, in terms of the number of people to be screened and the number of cases of blindness which might be prevented.
Prevalence, incidence, and natural course of diabetic retinopathy Diabetic retinopathy is a manifestation of diabetic microangiopathy.4 It is thought to evolve through several stages (fig 1) , background (early) retinopathy generally progressing either to maculopathy or to proliferative retinopathy. Proliferative retinopathy is more characteristic of early onset diabetes, whereas maculopathy is more characteristic of late onset diabetes. Both types of retinopathy can lead to blindness. Hereafter we refer to these two types of retinopathy as serious diabetic retinopathy.
The prevalence of diabetic retinopathy has been measured in several population based studies.58 The findings suggest that the prevalence of the more severe grades ranges from about 3%5 8 to 10%67 of diabetics.
Dwyer et al estimated the incidence of proliferative retinopathy among diabetics to be 1 6/1000 person years. 8 The incidence of maculopathy can be estimated by using data from the study of Burns-Cox and Hart.9 They found that maculopathy was 2-6 times as common as proliferative retinopathy, which suggests that the incidence of maculopathy is about 4 2/1000 person years (4 2=2 6x [1] [2] [3] [4] [5] [6] ). An estimate of the incidence of serious diabetic retinopathy is therefore 5 8/1000 person years (5-8=1I6+4-2). Sorsby presented age specific incidence rates of blindness due to diabetic retinopathy in England and Wales.'°By applying these rates to the underlying population" it can be calculated that roughly 460 new cases of blindness due to diabetic retinopathy may be expected to occur each year in people aged under 70 (table I) .
There is little information on the average duration of each stage of the natural course of diabetic retinopathy. Dwyer et al, however, reported that 20 years after the initial diagnosis of diabetes the cumulative incidence of retinopathy was 34 5%, whereas the cumulative incidence of proliferative retinopathy was 5%.8 This suggests a fairly slow progression to the more severe forms of retinopathy in most cases and raises the possibility of detection of retinopathy at an early stage followed by appropriate intervention.
Treatment
There is good evidence that treatment of diabetic retinopathy by argon laser or xenon arc photocoagulation ofthe retinal tissue is effective. Several randomised controlled trials in which the eyes of patients were randomised either to receive or not to receive photocoagulation have been performed. [12] [13] [14] [15] [16] [17] [18] Measures of outcome were either blindness or deterioration in visual acuity as measured by a decrease of two lines or more in the number of lines of a visual acuity chart which could be read. the matched odds ratio, is the ratio of the number of patients who suffered blindness in the treated eye but not the untreated eye to the number who suffered blindness in the untreated eye but not the treated eye. Information on people who suffered blindness in both As only one eye is needed for sight the reduction in blindness in a population will be greater than 61u' because the effect of treatment in one eye is not aiv identical with the effect in the other eye. If the effect oi treatment in one eye is completely unrelated to the effect in the other, then the 61% reduction in blindness per eye is equivalent to an 85% reduction in blindness per person, as the probability of going blind in both treated eyes is 0 39x0 39, or 0-15. The true population estimate is likely to lie between these values and so in our subsequent calculations we have assumed that the reduction in blindness will be 73%, the average of the maximum and minimum estimates. This figure is arbitrary but reasonable and allows us to estimate the effect of screening in practice. Alternative figures can be adopted and easily applied.
Screening
The long term impact on visual acuity of a screening programme for the detection of serious diabetic retinopathy does not seem to have been evaluated. Nevertheless, in several reports the ability of ophthalmic opticians92' and of ophthalmologists and diabetologists' to detect diabetic retinopathy has been examined. Burns-Cox and Hart reported results from a programme in which opticians screened diabetics for retinopathy.9 In that programme, conducted in the Frenchay health district, diabetics in hospital wards or attending diabetic clinics, general practitioners, or ophthalmic opticians were invited to visit opticians for annual eye checks. For each diabetic patient screened the corrected visual acuity and the retinal findings were recorded by an optician and forwarded to the investigators. In general, screened subjects whose retinas were normal or showed minimal background changes were not referred to ophthalmologists for further assessment (screen negative subjects), whereas those with more 
For several reasons our estimate of the benefit of screening is probably conservative. Firstly, and most importantly, a screening programme in diabetics under the age of 70 would prevent some cases of blindness in diabetics over 70. If the average time between treatment and the onset of blindness is five years calculations along the lines of those in tables I-IV suggest that this would amount to around 70 cases of blindness among the over 70s being prevented a year. Secondly, registration of the blind is incompletel'23 so that the incidence rates shown in table I are probably underestimates of the true incidence rates. Thirdly, the assumed detection rate of 88% applies to the prevalence screening examination. The detection rate for the whole screening process might be higher because some cases missed at the prevalence screening examination might be detected at subsequent examinations when the disease was still treatable. Fourthly, in the absence of information on the incidence rate of blindness due to diabetic retinopathy in people aged 65 or more we assumed that they were the same as those in people aged 60-64. This is probably not an unreasonable assumption but may have contributed to underestimation of the benefit. We have assumed a compliance rate of 100%. In practice there would be less than a 100% response to the invitation to be screened. Compliance, however, would probably be high, as diabetics would be motivated to participate in such programmes because of their knowledge about their disease. Figure 2 shows the estimated number of people who would be involved in a screening programme in which all diabetics under the age of 70 in England and Wales were invited each year for a screening examination together with the numbers who would be expected to need treatment at the prevalence screening examination and in typical subsequent years. Figure 2 BMJ VOLUME 299
